Processing

Please wait...

Settings

Settings

Goto Application

1. AR095349 - COMPUESTO Y COMPOSICIÓN FARMACÉUTICAMENTE ACEPTABLE, ÚTIL PARA TRATAR ENFERMEDAD O TRASTORNO TAL COMO LA ENFERMEDAD DE HUNTINGTON U OTRA PATOLOGÍA NEURODEGENERATIVA

Office
Argentina
Application Number P140101053
Application Date 14.03.2014
Publication Number 095349
Publication Date 07.10.2015
Publication Kind A1
IPC
C07D 231/14
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
DHETEROCYCLIC COMPOUNDS
231Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
02not condensed with other rings
10having two or three double bonds between ring members or between ring members and non-ring members
14with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
C07D 231/22
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
DHETEROCYCLIC COMPOUNDS
231Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
02not condensed with other rings
10having two or three double bonds between ring members or between ring members and non-ring members
14with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
18One oxygen or sulfur atom
20One oxygen atom attached in position 3 or 5
22with aryl radicals attached to ring nitrogen atoms
C07D 401/04
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
DHETEROCYCLIC COMPOUNDS
401Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
02containing two hetero rings
04directly linked by a ring-member-to-ring- member bond
C07D 403/04
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
DHETEROCYCLIC COMPOUNDS
403Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/167
02containing two hetero rings
04directly linked by a ring-member-to-ring- member bond
C07D 409/04
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
DHETEROCYCLIC COMPOUNDS
409Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
02containing two hetero rings
04directly linked by a ring-member-to-ring- member bond
A61K 31/40
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
33Heterocyclic compounds
395having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
40having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
CPC
C07D 231/14
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
DHETEROCYCLIC COMPOUNDS
231Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
02not condensed with other rings
10having two or three double bonds between ring members or between ring members and non-ring members
14with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
C07D 231/22
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
DHETEROCYCLIC COMPOUNDS
231Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
02not condensed with other rings
10having two or three double bonds between ring members or between ring members and non-ring members
14with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
18One oxygen or sulfur atom
20One oxygen atom attached in positions 3 or 5
22with aryl radicals attached to ring nitrogen atoms
C07D 401/04
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
DHETEROCYCLIC COMPOUNDS
401Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
02containing two hetero rings
04directly linked by a ring-member-to-ring-member bond
C07D 403/04
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
DHETEROCYCLIC COMPOUNDS
403Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
02containing two hetero rings
04directly linked by a ring-member-to-ring-member bond
C07D 409/04
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
DHETEROCYCLIC COMPOUNDS
409Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
02containing two hetero rings
04directly linked by a ring-member-to-ring-member bond
C07D 207/34
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
DHETEROCYCLIC COMPOUNDS
207Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
02with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
30having two double bonds between ring members or between ring members and non-ring members
34with heteroatoms or with carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
Applicants CHDI FOUNDATION, INC.
Inventors CELIA DOMINGUEZ
IGNACIO MUOZ
MICHEL MAILLARD
HUW D. VATER
REBECCA E. JARVIS
CHRISTOPHER A. LUCKHURST
ROLAND W. BURLI
GRANT WISHART

Priority Data 61/785551 14.03.2013 US
Title
(ES) COMPUESTO Y COMPOSICIÓN FARMACÉUTICAMENTE ACEPTABLE, ÚTIL PARA TRATAR ENFERMEDAD O TRASTORNO TAL COMO LA ENFERMEDAD DE HUNTINGTON U OTRA PATOLOGÍA NEURODEGENERATIVA
Abstract
(ES) Reivindicación 1: Un compuesto de fórmula (1) o alguna de sus sales farmacéuticamente aceptable, caracterizado porque X es CR⁴ o N; R es seleccionado de entre C(O)NH(OH) y -N(OH)C(O)R⁷; R¹ es arilo opcionalmente sustituido o heteroarilo opcionalmente sustituido; R² es seleccionado de entre hidrógeno, alquilo C₁₋₄, halo, haloalquilo C₁₋₄ y nitrilo; R³ es seleccionado de entre -OR⁵, -NR⁵R⁶, alquilo opcionalmente sustituido, aralquilo opcionalmente sustituido, arilo opcionalmente sustituido, heteroarilo opcionalmente sustituido, heterocicloalquilo opcionalmente sustituido, heterocicloalquenilo opcionalmente sustituido, cicloalquenilo opcionalmente sustituido y cicloalquilo opcionalmente sustituido; R⁴ es seleccionado de entre hidrógeno, halo, alquilo C₁₋₄ o haloalquilo C₁₋₄; R⁵ y R⁶ son seleccionados independientemente de entre hidrógeno, alquilo C₁₋₄ opcionalmente sustituido, haloalquilo C₁₋₄ opcionalmente sustituido, arilo opcionalmente sustituido, heteroarilo opcionalmente sustituido, heterocicloalquilo opcionalmente sustituido, cicloalquilo opcionalmente sustituido, aralquilo opcionalmente sustituido y heteroaralquilo opcionalmente sustituido; o R⁵ y R⁶, junto con el átomo de nitrógeno al que están unidos, forman un heterocicloalquilo opcionalmente sustituido; y R⁷ es seleccionado de entre hidrógeno, alquilo C₁₋₄ y haloalquilo C₁₋₄.
Related patent documents